The Effect of Zoledronic Acid on the Volume of the Fusion-Mass in Lumbar Spinal Fusion

• Published in: Clinics in orthopedic surgery Vol. 5; no. 4; pp. 292 - 297
• Main Authors: Park, Ye-Soo, Kim, Hong-Sik, Baek, Seung-Wook, Kong, Dong-Yi, Ryu, Jeong-Ah
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Orthopaedic Association 01.12.2013; 대한정형외과학회
• Subjects: Aged; Aged, 80 and over; Bone Density Conservation Agents - therapeutic use; Diphosphonates - therapeutic use; Female; Humans; Imidazoles - therapeutic use; Lumbar Vertebrae - diagnostic imaging; Lumbar Vertebrae - drug effects; Lumbar Vertebrae - pathology; Lumbar Vertebrae - surgery; Male; Middle Aged; Original; Osteoporosis - drug therapy; Pain Measurement; Pain, Postoperative; Quality of Life; Radiography; Retrospective Studies; Spinal Fusion - adverse effects; Spinal Fusion - methods; Spinal Stenosis - diagnostic imaging; Spinal Stenosis - pathology; Spinal Stenosis - surgery; Treatment Outcome; 정형외과학; Zoledronic acid; Osteoporosis; Bisphosphonate; Fusion-mass; Spinal fusion
• ISSN: 2005-291X; 2005-4408; 2005-4408
• DOI: 10.4055/cios.2013.5.4.292

Few studies have explored the effects of bisphosphonates on bony healing in patients undergoing spinal fusion surgery. Most previous studies used animal models and found that bisphosphonate shows negative effects on spinal fusion consolidation. We intended to evaluate the effect of a single-dose of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. A retrospective review was carried out on 44 patients with symptomatic degenerative lumbar spinal stenosis who underwent one or two-level posterolateral fusion from January 2008 and January 2011. They were divided into 4 groups: group 1, autograft and zoledronic acid; group 2, allograft and zoledronic acid; group 3, autograft alone; and group 4, allograft alone. Functional radiography and three-dimensional computed tomography scans were used to evaluate and quantify the volume of the fusion-mass. The visual analog scale (VAS), the Oswestry disability index (ODI), and the short form 36 (SF-36) were used to evaluate the clinical outcomes. The mean volume of the fusion-mass per level was 8,814 mm(3), 8,035 mm(3), 8,383 mm(3), and 7,550 mm(3) in groups 1, 2, 3, and 4, respectively, but there were no significant differences between the groups (p = 0.829). There were no significant decreases in the volume of the fusion-mass (p = 0.533) in the zoledronic acid groups (groups 1 and 2). The VAS, the ODI, and the SF-36 at the 6-month follow-up after surgery were not significantly different (p > 0.05) among the 4 groups. The VAS, the ODI, and the SF-36 were not correlated with the volume of the fusion-mass (p = 0.120, 0.609, 0.642). A single dose of zoledronic acid does not decrease the volume of the fusion-mass in patients undergoing spinal fusion with osteoporosis. Therefore, we recommend that zoledronic acid may be used after spinal fusion in osteoporotic patients.